Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
US |
|
M
|
Morgan Stanley
XHAM:DWD
|
US |
|
M
|
Macy's Inc
F:FDO
|
US |
|
M
|
Mabion SA
WSE:MAB
|
PL |
|
T
|
TD Synnex Corp
SWB:SUX
|
US |
|
Sanofi SA
F:SNW
|
FR |
|
N
|
NetApp Inc
F:NTA
|
US |
|
Zurich Insurance Group AG
F:ZFI1
|
CH |
|
Tudor Gold Corp
XTSX:TUD
|
CA |
|
Banco Santander SA
OTC:BCDRF
|
ES |
|
Funko Inc
NASDAQ:FNKO
|
US |
|
Akzo Nobel NV
AEX:AKZA
|
NL |
|
AAR Corp
NYSE:AIR
|
US |
|
Equitable Group Inc
TSX:EQB
|
CA |
Wall St Price Targets
ARQT Price Targets Summary
Arcutis Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ARQT is 35.32 USD with a low forecast of 33.33 USD and a high forecast of 37.8 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ARQT's stock price target?
Price Target
35.32
USD
According to Wall Street analysts, the average 1-year price target for
ARQT is 35.32 USD with a low forecast of 33.33 USD and a high forecast of 37.8 USD.
What is the Revenue forecast for Arcutis Biotherapeutics Inc?
Projected CAGR
18%
The compound annual growth rate for Revenue over the next 8 years is 18%.